Daniel Waterkamp

10.7k total citations · 2 hit papers
39 papers, 3.9k citations indexed

About

Daniel Waterkamp is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Daniel Waterkamp has authored 39 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 8 papers in Cancer Research. Recurrent topics in Daniel Waterkamp's work include Cancer Immunotherapy and Biomarkers (26 papers), Colorectal Cancer Treatments and Studies (19 papers) and Lung Cancer Treatments and Mutations (9 papers). Daniel Waterkamp is often cited by papers focused on Cancer Immunotherapy and Biomarkers (26 papers), Colorectal Cancer Treatments and Studies (19 papers) and Lung Cancer Treatments and Mutations (9 papers). Daniel Waterkamp collaborates with scholars based in United States, Switzerland and Spain. Daniel Waterkamp's co-authors include Marcin Kowanetz, Achim Rittmeyer, Alexander I. Spira, Marcus Ballinger, Julien Mazières, Johan Vansteenkiste, Keunchil Park, Louis Fehrenbacher, Alan Sandler and Wei Zou and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Daniel Waterkamp

39 papers receiving 3.8k citations

Hit Papers

Atezolizumab versus docetaxel for patients with previousl... 2013 2026 2017 2021 2016 2013 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
    2016 2.1k citations Louis Fehrenbacher, Alexander I. Spira et al. The Lancet profile →
  2. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial
    2013 438 citations David Cunningham, István Láng et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel Waterkamp United States 21 3.5k 1.9k 813 530 354 39 3.9k
Davey B. Daniel United States 19 2.2k 0.6× 2.1k 1.1× 362 0.4× 688 1.3× 194 0.5× 82 3.3k
Michael McCleod United States 17 2.5k 0.7× 1.7k 0.9× 341 0.4× 276 0.5× 241 0.7× 44 3.0k
Martin Šmakal United States 11 2.1k 0.6× 896 0.5× 293 0.4× 378 0.7× 385 1.1× 26 2.6k
Rachel E. Sanborn United States 25 2.8k 0.8× 1.3k 0.7× 1.1k 1.4× 292 0.6× 151 0.4× 154 3.7k
Alexander I. Spira United States 10 2.2k 0.6× 1.3k 0.7× 636 0.8× 384 0.7× 102 0.3× 19 2.5k
Venice Archer United Kingdom 9 3.6k 1.0× 3.6k 1.9× 276 0.3× 663 1.3× 183 0.5× 16 4.6k
Maria Błasińska-Morawiec Poland 17 1.7k 0.5× 897 0.5× 378 0.5× 337 0.6× 374 1.1× 37 2.5k
Gene Grant Finley United States 19 3.3k 0.9× 2.2k 1.2× 690 0.8× 466 0.9× 71 0.2× 70 4.4k
Achim Rittmeyer United States 26 4.9k 1.4× 3.5k 1.9× 1.1k 1.3× 687 1.3× 81 0.2× 91 5.7k
Z. Alexander Cao United States 18 3.7k 1.1× 1.1k 0.6× 860 1.1× 769 1.5× 135 0.4× 40 4.4k

Countries citing papers authored by Daniel Waterkamp

Since Specialization
Citations

This map shows the geographic impact of Daniel Waterkamp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Waterkamp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Waterkamp more than expected).

Fields of papers citing papers by Daniel Waterkamp

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Waterkamp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Waterkamp. The network helps show where Daniel Waterkamp may publish in the future.

Co-authorship network of co-authors of Daniel Waterkamp

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Waterkamp. A scholar is included among the top collaborators of Daniel Waterkamp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Waterkamp. Daniel Waterkamp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Liu, Stephen V., D. Ross Camidge, Scott Gettinger, et al.. (2018). Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non–small-cell lung cancer. European Journal of Cancer. 101. 114–122. 38 indexed citations
2.
3.
Liu, Stephen V., Martin Reck, Tony Mok, et al.. (2017). P3.02c-041 IMpower133: A Phase I/III Study of 1L Atezolizumab with Carboplatin and Etoposide in Patients with Extensive-Stage SCLC. Journal of Thoracic Oncology. 12(1). S1299–S1299. 1 indexed citations
4.
Rittmeyer, Achim, David C. Smith, Johan Vansteenkiste, et al.. (2017). Updated survival and biomarker analyses of a randomized phase II study of atezolizumab vs. docetaxel in 2L/3L NSCLC (POPLAR). Pneumologie. 71(S 01). S1–S125. 4 indexed citations
5.
Liu, Stephen V., D. Ross Camidge, Scott Gettinger, et al.. (2017). Atezolizumab (atezo) plus platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): Update from a phase Ib study.. Journal of Clinical Oncology. 35(15_suppl). 9092–9092. 24 indexed citations
6.
Kowanetz, Marcin, Wei Zou, David S. Shames, et al.. (2017). OA20.01 Tumor Mutation Burden (TMB) is Associated with Improved Efficacy of Atezolizumab in 1L and 2L+ NSCLC Patients. Journal of Thoracic Oncology. 12(1). S321–S322. 61 indexed citations
7.
Horn, Leora, Martin Reck, Tony Mok, et al.. (2016). PS01.57: IMpower133: a Phase I/III Study of 1L Atezolizumab with Carboplatin and Etoposide in Patients with Extensive-Stage SCLC. Journal of Thoracic Oncology. 11(11). S305–S306. 3 indexed citations
8.
Barlési, Fabrice, K. Park, Fortunato Ciardiello, et al.. (2016). Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC. Annals of Oncology. 27. vi581–vi581. 56 indexed citations
9.
Kowanetz, Marcin, Wei Zou, David S. Shames, et al.. (2016). Tumor mutation load assessed by FoundationOne (FM1) is associated with improved efficacy of atezolizumab (atezo) in patients with advanced NSCLC. Annals of Oncology. 27. vi23–vi23. 34 indexed citations
10.
Reck, Martin, Vassiliki A. Papadimitrakopoulou, Federico Cappuzzo, et al.. (2016). Phase III clinical trials in chemotherapy-naive patients with advanced NSCLC assessing the combination of atezolizumab and chemotherapy. Annals of Oncology. 27. vi451–vi451. 4 indexed citations
11.
Fehrenbacher, Louis, Alexander I. Spira, Marcus Ballinger, et al.. (2016). Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. The Lancet. 387(10030). 1837–1846. 2112 indexed citations breakdown →
12.
Horn, Leora, Martin Reck, Tony Mok, et al.. (2016). A Phase III study of atezolizumab with carboplatin plus etoposide in patients with extensive-stage small cell lung cancer (IMpower133). Annals of Oncology. 27. vi496–vi496. 3 indexed citations
13.
Smith, David A., Johan Vansteenkiste, Louis Fehrenbacher, et al.. (2016). Updated survival and biomarker analyses of a randomized phase II study of atezolizumab vs docetaxel in 2L/3L NSCLC (POPLAR).. Journal of Clinical Oncology. 34(15_suppl). 9028–9028. 22 indexed citations
14.
Mok, Tony, Federico Cappuzzo, Robert M. Jotte, et al.. (2015). 356TiP Phase III clinical trials of atezolizumab in combination with chemotherapy in chemotherapy-naive patients with advanced NSCLC. Annals of Oncology. 26. ix103–ix103. 3 indexed citations
15.
Bendell, Johanna C., John D. Powderly, Christopher H. Lieu, et al.. (2015). Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 33(3_suppl). 704–704. 86 indexed citations
16.
Gruenberger, Thomas, John Bridgewater, Ian Chau, et al.. (2014). Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Annals of Oncology. 26(4). 702–708. 225 indexed citations
17.
Adam, René, John Bridgewater, Ian Chau, et al.. (2013). Randomised, Phase 2 Study (OLIVIA) of Bevacizumab Plus mFOLFOX6 or Folfoxiri in Patients with Initially Unresectable Colorectal Cancer Liver Metastases. Annals of Oncology. 24. iv21–iv21. 3 indexed citations
18.
Saunders, Mark, István Láng, Eugenio Marcuello, et al.. (2013). Results According to Age in Avex, a Randomized Phase 3 Trial of Bevacizumab with Capecitabine for Elderly Patients with Mcrc. Annals of Oncology. 24. iv23–iv23. 1 indexed citations
19.
Cunningham, David, István Láng, Eugenio Marcuello, et al.. (2013). Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. The Lancet Oncology. 14(11). 1077–1085. 438 indexed citations breakdown →
20.
Saunders, Mark, István Láng, Eugenio Marcuello, et al.. (2013). Efficacy and safety according to age subgroups in AVEX, a randomized phase III trial of bevacizumab in combination with capecitabine for the first-line treatment of elderly patients with metastatic colorectal cancer.. Journal of Clinical Oncology. 31(15_suppl). 3521–3521. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Davey B. Daniel Breakdown of academic impact, for papers by Michael McCleod Breakdown of academic impact, for papers by Martin Šmakal Breakdown of academic impact, for papers by Rachel E. Sanborn Breakdown of academic impact, for papers by Alexander I. Spira Breakdown of academic impact, for papers by Venice Archer Breakdown of academic impact, for papers by Maria Błasińska-Morawiec Breakdown of academic impact, for papers by Gene Grant Finley Breakdown of academic impact, for papers by Achim Rittmeyer Breakdown of academic impact, for papers by Z. Alexander Cao
Rankless by CCL
2026